D - Description
|
Quality
Management |
Training and
Education |
Public
Involvement |
| Description | |
|---|---|
Name |
EUNETHYDIS - European Network for Hyperkinetic Disorders |
| Year of foundation | 1989 |
| Preterm and/or term newborn | No |
| Infants from 1 month to less than 24 months of age | No |
| Children from 2 years to less than 12 years of age | Yes |
| Adolescents from 12 years to less than 18 years | Yes |
| Paediatric age ranges of study participants covered by the network | 2-17 years |
| Multispeciality? Specify | multispeciality |
| Speciality/disease specific? Specify | Attention Deficit Hyperactivity Disorder (ADHD) and its comorbidities. |
| Conditions covered? Specify | ADHD, Autism, Oppositional Deficant Disorder, Conduct Disorder, Dyslexia, Developmental Coordination Disorder, Anxiety, Depression. |
| Procedure/Intervention specific? Specify | Pharmcology, Psychotherapies (including Behavioural Therapy, Family Therapy), Neurofeedback, Dietry Interventions. |
| Number of collaborating countries | 12 |
| List of collaborating countries | Belgium, Denmark, France, Germany, Holland, Hungary, Italy, Norway, Spain, Sweden, Switzerland, UK. |
| Number of collaborating centres | 18 |
| List of collaborating centres | see attached list |
| Type of activity/studies | |
| Clinical Studies | Yes |
| Experimental research | Yes |
| Other activity | Development of Clinical Guidelines for Practitioners. Monitoring Clinical Practice (e.g. ADORE, a large 2 year European Observational study of ADHD care). Pharmacovigilance (e.g. ADDUCE [Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects] an EU - FP7 pharmacovigilence study of methylphenidate). Neuroscientific research (includes neuroimaging, neurophysiological and neuropsychological studies many of which are linked to psychopharmacological designs). Molecular Genetics. |